MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
4.440
-0.110
-2.42%
After Hours: 4.460 +0.02 +0.45% 18:45 06/30 EDT
OPEN
4.390
PREV CLOSE
4.550
HIGH
4.647
LOW
4.350
VOLUME
129.59K
TURNOVER
--
52 WEEK HIGH
59.40
52 WEEK LOW
3.800
MARKET CAP
5.53M
P/E (TTM)
-0.0218
1D
5D
1M
3M
1Y
5Y
1D
Aptevo Therapeutics Secures Grant for APVO451 Development
TipRanks · 3h ago
APTEVO THERAPEUTICS - CARE FUND TO PROVIDE $1.5 MLN FUNDING FOR APVO451 IND-ENABLING STUDIES - SEC FILING
Reuters · 3h ago
Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund
TipRanks · 11h ago
Aptevo wins $1.5 million Andy Hill CARE Fund grant for APVO451 IND-enabling work
PUBT · 11h ago
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
Barchart · 16h ago
Weekly Report: what happened at APVO last week (0622-0626)?
Weekly Report · 1d ago
Aptevo Therapeutics posts investor presentation on multispecific immunotherapies for cancer, led by mipletamig in AML
PUBT · 5d ago
Aptevo Therapeutics files Form 3 initial beneficial ownership statement for Niowave Inc
PUBT · 06/22 15:45
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.